Table 3.
Adjustments of Immunosuppressive Drug Regimen in Selected Cohort Studies/Case Series of Transplant Recipients Infected With SARS-CoV-2
| Antimetabolites, n/N (%)* |
Calcineurin Inhibitors, n/N (%)† |
Steroids, n/N (%)‡ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Transplanted Organ(s) | Study Cohort, No. | ↔ | X | ↓ | ↑ | ↔ | X | ↓ | ↑ | ↔ | X | ↓ | ↑ |
| Coll et al. [177] | Kidney, HSCT, liver, lung, pancreas, multivisceral | 778 | 92/389 (23.7) | 273/389 (70.2) | 24/389 (6.2) | 0 | 175/495 (35.4) | 181/495 (36.6) | 134/495 (27.1) | 5/495 (1) | 197/460 (42.8) | 8/460 (1.7) | 2/460 (0.4) | 253/460 (55) |
| Kute et al. [179] | Kidney | 250 | 0 | 188/250 (75.2) | 62/250 (24.8) | 0 | 165/236 (69.9) | 21/236 (8.9) | 50/236 (21.2) | 0 | 150/250 (60) | 0 | 0 | 100/250 (40) |
| Bechetti et al. [119] | Liver | 57 | 15/26 (57.7) | 10/26 (38.5) | 1/26 (3.8) | 0 | 31/50 (62) | 7/50 (14) | 12/50 (24) | 0 | 10/10 (100) | 0 | 0 | 0 |
| Lubetzky et al. [164] | Kidney | 54 | 13/52‡ (25) | 24/52 (46.2) | 15/52 (28.8) | 0 | 35/52 (67.3) | 0 | 17/52 (32.7) | 0 | 22/27 (81.5) | 0 | 0 | 5/27 (18.5) |
| Felldin et al. [132] | Kidney, liver, heart, lung, liver-kidney, kidney-heart | 53 | 17/41 (41.5) | 19/41 (46.3) | 5/41 (12.2) | 0 | 42/53 (79.2) | 3/53 (5.7) | 8/53 (15.1) | 0 | 30/40 (75) | 0 | 0 | 10/40 (25) |
| Total | 1192 | 137/758 (18.1) | 514/758 (67.8) | 107/758 (14.1) | 0 | 448/886 (50.6) | 212/886 (23.9) | 221/886 (24.9) | 5/886 (0.6) | 409/787 (52) | 8/787 (1) | 2/787 (0.3) | 368/787 (46.8) | |
↔, no (substantial) change; ↓, dose reduction; ↑, dose increase; HSCT, hematopoietic stem cell transplant; n, quantity; N, patient population among study cohort that initially received the respective treatment; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; X, withdrawal.
⁎
Azathioprine and/or mycophenolate mofetil.
†
Cyclosporine and/or tacrolimus.
‡
No reduction/≤50% reduction.